BACKGROUND: External beam radiation therapy can be used to treat pelvic tumors in dogs, but its utility is limited by lack of efficacy data and associated late complications. HYPOTHESIS/ OBJECTIVES: The objective of this study was to assess local tumor control, overall survival, and toxicosis after intensity-modulated and image-guided radiation therapy (IM/IGRT) for treatment of genitourinary carcinomas (CGUC) in dogs. ANIMALS: 21 client-owned dogs. METHODS: A retrospective study was performed. Medical records of dogs for which there was intent to treat with a course of definitive-intent IM/IGRT for CGUC between 2008 and 2011 were reviewed. Descriptive and actuarial statistics comprised the data analysis. RESULTS: Primary tumors were located in the prostate (10), urinary bladder (9), or urethra (2). The total radiation dose ranged from 54-58 Gy, delivered in 20 daily fractions. Grade 1 and 2 acute gastrointestinal toxicoses developed in 33 and 5% of dogs, respectively. Grade 1 and 2 acute genitourinary and grade 1 acute integumentary toxicoses were documented in 5, 5, and 20% of dogs, respectively. Four dogs experienced late grade 3 gastrointestinal or genitourinary toxicosis. The subjective response rate was 60%. The median event-free survival was 317 days; the overall median survival time was 654 days. Neither local tumor control nor overall survival was statistically dependent upon location of the primary tumor. CONCLUSIONS AND CLINICAL IMPORTANCE: IM/IGRT is generally well-tolerated and provides an effective option for locoregional control of CGUC. As compared with previous reports in the veterinary literature, inclusion of IM/IGRT in multimodal treatment protocols for CGUC can result in superior survival times; controlled prospective evaluation is warranted.
BACKGROUND: External beam radiation therapy can be used to treat pelvic tumors in dogs, but its utility is limited by lack of efficacy data and associated late complications. HYPOTHESIS/ OBJECTIVES: The objective of this study was to assess local tumor control, overall survival, and toxicosis after intensity-modulated and image-guided radiation therapy (IM/IGRT) for treatment of genitourinary carcinomas (CGUC) in dogs. ANIMALS: 21 client-owned dogs. METHODS: A retrospective study was performed. Medical records of dogs for which there was intent to treat with a course of definitive-intent IM/IGRT for CGUC between 2008 and 2011 were reviewed. Descriptive and actuarial statistics comprised the data analysis. RESULTS:Primary tumors were located in the prostate (10), urinary bladder (9), or urethra (2). The total radiation dose ranged from 54-58 Gy, delivered in 20 daily fractions. Grade 1 and 2 acute gastrointestinal toxicoses developed in 33 and 5% of dogs, respectively. Grade 1 and 2 acute genitourinary and grade 1 acute integumentary toxicoses were documented in 5, 5, and 20% of dogs, respectively. Four dogs experienced late grade 3 gastrointestinal or genitourinary toxicosis. The subjective response rate was 60%. The median event-free survival was 317 days; the overall median survival time was 654 days. Neither local tumor control nor overall survival was statistically dependent upon location of the primary tumor. CONCLUSIONS AND CLINICAL IMPORTANCE: IM/IGRT is generally well-tolerated and provides an effective option for locoregional control of CGUC. As compared with previous reports in the veterinary literature, inclusion of IM/IGRT in multimodal treatment protocols for CGUC can result in superior survival times; controlled prospective evaluation is warranted.
Authors: Marcus L Bradbury; Christine M Mullin; Shaban D Gillian; Chick Weisse; Philip J Bergman; Michelle A Morges; Lauren R May; David M Vail; Craig A Clifford Journal: Can Vet J Date: 2021-02 Impact factor: 1.008
Authors: Sarah B Rippy; Heather L Gardner; Sandra M Nguyen; Emma E Warry; Roberta A Portela; William Tod Drost; Eric T Hostnik; Eric M Green; Dennis J Chew; Juan Peng; Cheryl A London Journal: BMC Vet Res Date: 2016-11-17 Impact factor: 2.741
Authors: Deborah W Knapp; Deepika Dhawan; José A Ramos-Vara; Timothy L Ratliff; Gregory M Cresswell; Sagar Utturkar; Breann C Sommer; Christopher M Fulkerson; Noah M Hahn Journal: Front Oncol Date: 2020-01-21 Impact factor: 6.244
Authors: Maureen A Griffin; William T N Culp; Michelle A Giuffrida; Peter Ellis; Joanne Tuohy; James A Perry; Allison Gedney; Cassie N Lux; Milan Milovancev; Mandy L Wallace; Jonathan Hash; Kyle Mathews; Julius M Liptak; Laura E Selmic; Ameet Singh; Carrie A Palm; Ingrid M Balsa; Philipp D Mayhew; Michele A Steffey; Robert B Rebhun; Jenna H Burton; Michael S Kent Journal: J Vet Intern Med Date: 2019-11-13 Impact factor: 3.333
Authors: Valeria Meier; Chris Staudinger; Stephan Radonic; Jürgen Besserer; Uwe Schneider; Linda Walsh; Carla Rohrer Bley Journal: Vet Comp Oncol Date: 2021-01-06 Impact factor: 2.613